Discovery of pan-EphB tyrosine kinase inhibitor for metabolic syndrome sparing EphB3 signaling in mice
The global prevalence of metabolic syndrome had created one of the most pressing public health dilemmas and significant financial burden to the healthcare system. Despite the surge of glucagon-like peptide-1 agonists, recent studies showed that 40 % of body weight loss is due to lean mass loss, rais...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2025-09-01
|
| Серии: | Pharmacological Research |
| Предметы: | |
| Online-ссылка: | http://www.sciencedirect.com/science/article/pii/S1043661825003251 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|
